Filtered By:
Cancer: Thyroid Cancer

This page shows you your search results in order of date. This is page number 12.

Order by Relevance | Date

Total 208 results found since Jan 2013.

Microrna-199a-5p Functions as a Tumor Suppressor via Suppressing Connective Tissue Growth Factor (CTGF) in Follicular Thyroid Carcinoma.
CONCLUSIONS Our study proves that the CTGF gene is a target of miR-199a-5p, demonstrating the negatively related association between CTGF and miR-199a. These findings suggest that miR-199a-5p might be a novel therapeutic target in the treatment of follicular thyroid carcinoma. PMID: 27062921 [PubMed - in process]
Source: Medical Science Monitor - April 13, 2016 Category: Research Tags: Med Sci Monit Source Type: research

GSE80135 Prox1 (Prosper-related homeobox 1) transcription factor depletion effect on CGTH-W-1 cells.
Contributors : Magdalena Rudzińska ; Joanna Ledwoń ; Justyna Sikorska ; Katarzyna Paczkowska ; Agnieszka Paziewska ; Michal Mikula ; Jerzy Ostrowski ; Barbara CzarnockaSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensAnalysis of CGTH-W-1 follicular thyroid carcinoma cells transcriptome following 48 hrs siRNA-mediated depletion of PROX1. PROX1 is a homeobox transcription factor. PROX1 depletion decreases migratory ability, motility and invasivness and induces profound cytoskeleton changes of CGTH-W-1 cells. Results provide insight into the role of PROX1 in the thyroid cancer.
Source: GEO: Gene Expression Omnibus - April 12, 2016 Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Homo sapiens Source Type: research

Oncogenic BRAF Deletions Functioning as Homodimers Research Articles
This study discovered oncogenic BRAF deletions with a distinct activation mechanism dependent on the BRAF dimer formation in tumor cells. LY3009120 is active against these cells and represents a potential treatment option for patients with cancer with these BRAF deletions, or other atypical BRAF mutations where BRAF functions as a dimer. Cancer Discov; 6(3); 300–15. ©2016 AACR. This article is highlighted in the In This Issue feature, p. 217
Source: Cancer Discovery - March 6, 2016 Category: Cancer & Oncology Authors: Chen, S.-H., Zhang, Y., Van Horn, R. D., Yin, T., Buchanan, S., Yadav, V., Mochalkin, I., Wong, S. S., Yue, Y. G., Huber, L., Conti, I., Henry, J. R., Starling, J. J., Plowman, G. D., Peng, S.-B. Tags: Research Articles Source Type: research

Downregulation of vascular endothelial growth factor receptor-2 under oxidative stress conditions is mediated by β-transduction repeat-containing protein via glycogen synthase kinase-3β signaling.
Abstract Vascular endothelial growth factor receptor-2 (VEGFR-2), which is a key determinant of the angiogenecic response, is decreased in diabetic mice under oxidative stress. β-transduction repeat-containing protein (β-TrCP) has been reported to participate in VEGFR-2 degradation in thyroid cancer cells. Additionally, glycogen synthase kinase-3β (GSK‑3β) acts as a mediator in the β-TrCP-induced degradation of several proteins. However, the role played by β-TrCP and GSK‑3β in the degradation of VEGFR-2 in endothelial cells where hyperglycemia had been induced was not fully understood. In the present ...
Source: International Journal of Molecular Medicine - February 18, 2016 Category: Molecular Biology Authors: Wu W, Zhang D, Pan D, Zuo G, Ren X, Chen S Tags: Int J Mol Med Source Type: research

Cellular apoptosis susceptibility (CAS) is overexpressed in thyroid carcinoma and maintains tumor cell growth: A potential link to the BRAFV600E mutation.
Abstract Thyroid carcinoma is among the most common malignant endocrine neoplasms with a rising incidence. Genetic alterations occurring in thyroid cancer frequently affect the RAS/RAF/MEK/ERK-pathway such as the oncogenic, kinase-activating BRAFV600E mutation. Nuclear transport receptors including importins and exportins represent an important part of the nuclear transport machinery providing nucleo-cytoplasmic exchange of macromolecules. The role of nuclear transport receptors in the development and progression of thyroid carcinomas is largely unknown. Here, we studied the expression and function of the exportin...
Source: International Journal of Oncology - February 9, 2016 Category: Cancer & Oncology Authors: Holzer K, Drucker E, Oliver S, Winkler J, Eiteneuer E, Herpel E, Breuhahn K, Singer S Tags: Int J Oncol Source Type: research

ST6GalNAcII mediates tumor invasion through PI3K/Akt/NF-κB signaling pathway in follicular thyroid carcinoma.
In conclusion, taken together, our results imply that ST6GalNAcII activated the invasion in follicular thyroid cancer cells through regulating the activity of PI3K/Akt pathway. PMID: 26820593 [PubMed - as supplied by publisher]
Source: Oncology Reports - January 30, 2016 Category: Cancer & Oncology Tags: Oncol Rep Source Type: research

MAPK and SHH pathways modulate type 3 deiodinase expression in papillary thyroid carcinoma
In conclusion, sustained activation of the MAPK and SHH pathways modulate the levels of DIO3 expression in PTC. Importantly, DIO3 silencing was associated with decreases in cell proliferation, thus suggesting a D3 role in tumor growth and aggressiveness.
Source: Endocrine-Related Cancer - January 29, 2016 Category: Endocrinology Authors: Romitti, M., Wajner, S. M., Ceolin, L., Ferreira, C. V., Ribeiro, R. V. P., Rohenkohl, H. C., Weber, S. d. S., Lopez, P. L. d. C., Fuziwara, C. S., Kimura, E. T., Maia, A. L. Tags: Research Source Type: research

Germline PARP4 mutations in patients with primary thyroid and breast cancers
In conclusion, we identified PARP4 as a possible susceptibility gene of primary thyroid and breast cancer.
Source: Endocrine-Related Cancer - January 29, 2016 Category: Endocrinology Authors: Ikeda, Y., Kiyotani, K., Yew, P. Y., Kato, T., Tamura, K., Yap, K. L., Nielsen, S. M., Mester, J. L., Eng, C., Nakamura, Y., Grogan, R. H. Tags: Research Source Type: research

siRNA targeting RBP2 inhibits expression, proliferation, tumorigenicity and invasion in thyroid carcinoma cells.
In conclusion, the transfection of RBP2-siRNA into papillary thyroid carcinoma K1 cells suppressed the expression of RBP2 in these cells, and reduced their proliferation, invasion, migration and tumorigenic potential. Therefore, targeting RBP2 may be an efficient approach to control thyroid carcinoma. PMID: 26788140 [PubMed - as supplied by publisher]
Source: Oncology Letters - January 21, 2016 Category: Cancer & Oncology Tags: Oncol Lett Source Type: research

Increased Expression of FGF19 Contributes to Tumor Progression and Cell Motility of Human Thyroid Cancer
Conclusion Our data revealed that the increased expression of FGF19 might be involved in the malignant behaviors of thyroid cancer, highlighting its potential as a molecular marker for early diagnosis and as a possible target for therapeutic intervention of this disease.
Source: Otolaryngology - Head and Neck Surgery - January 6, 2016 Category: ENT & OMF Authors: Zhang, X., Wang, Z., Tian, L., Xie, J., Zou, G., Jiang, F. Tags: Endocrine Surgery Source Type: research

microRNA-137 is downregulated in thyroid cancer and inhibits proliferation and invasion by targeting EGFR
In conclusion, the present study showed that miR-137 downregulation is associated with malignant progression of thyroid cancer. miR-137 inhibits growth and invasion by targeting EGFR in thyroid cancer cells.
Source: Tumor Biology - December 22, 2015 Category: Cancer & Oncology Source Type: research

Histone deacetylase 3 indirectly modulates tubulin acetylation
Histone deacetylase 3 (HDAC3), a member of the Class I subfamily of HDACs, is found in both the nucleus and the cytoplasm. Its roles in the nucleus have been well characterized, but its cytoplasmic roles are still not elucidated fully. We found that blocking HDAC3 activity using MI192, a compound specific for HDAC3, modulated tubulin acetylation in the human prostate cancer cell line PC3. A brief 1 h treatment of PC3 cells with MI192 significantly increased levels of tubulin acetylation and ablated the dynamic behaviour of microtubules in live cells. siRNA-mediated knockdown (KD) of HDAC3 in PC3 cells, significan...
Source: Biochemical Journal - November 27, 2015 Category: Biochemistry Authors: Bacon, T., Seiler, C., Wolny, M., Hughes, R., Watson, P., Schwabe, J., Grigg, R., Peckham, M. Tags: Cell Research articles Source Type: research

miR-29a suppresses growth and metastasis in papillary thyroid carcinoma by targeting AKT3
Abstract MicroRNA-29a (miR-29a) has been reported to play important roles in tumor initiation, development, and metastasis in various cancers. However, the biological function and potential mechanisms of miR-29a in papillary thyroid carcinoma (PTC) remain unclear. In the present study, we discovered that miR-29a was frequently downregulated in PTC tissues, and its expression was significantly associated with tumor size, TNM stage, and lymph node metastasis. Functional assays showed that overexpression of miR-29a markedly suppressed PTC cell proliferation, migration, and invasion and promoted PTC apoptosis and cell...
Source: Tumor Biology - October 19, 2015 Category: Cancer & Oncology Source Type: research

Ribonucleotide reductase large subunit M1 plays a different role in the invasion and metastasis of papillary thyroid carcinoma and undifferentiated thyroid carcinoma
Abstract Ribonucleotide reductase (RR) has been reported to be associated with several types of cancer while the expression and role of RR in thyroid carcinoma (TC) has not been investigated. Here, we first examined the expression level of three RR subunit proteins (RRM1, RRM2, and RRM2B) in papillary thyroid carcinoma (PTC) and undifferentiated thyroid carcinoma (UTC) patient samples by immunohistochemistry. The results showed that RRM1 was higher expressed in 95.2 % cancer tissues compared with their adjacent normal tissues in 146 PTC samples. The expression level of RRM1 was positively correlated with T stage,...
Source: Tumor Biology - October 9, 2015 Category: Cancer & Oncology Source Type: research

Identification of thyroid tumor cell vulnerabilities through a siRNA-based functional screening.
Authors: Anania M, Gasparri F, Cetti E, Fraietta I, Todoerti K, Miranda C, Mazzoni M, Re C, Colombo R, Ukmar G, Camisasca S, Pagliardini S, Pierotti M, Neri A, Galvani A, Greco A Abstract The incidence of thyroid carcinoma is rapidly increasing. Although generally associated with good prognosis, a fraction of thyroid tumors are not cured by standard therapy and progress to aggressive forms for which no effective treatments are currently available. In order to identify novel therapeutic targets for thyroid carcinoma, we focused on the discovery of genes essential for sustaining the oncogenic phenotype of thyroid tum...
Source: Oncotarget - October 3, 2015 Category: Cancer & Oncology Tags: Oncotarget Source Type: research